ArticleWorld journal of urology2025

Do patients with intermediate-risk renal carcinoma who receive adjuvant pembrolizumab really benefit in recurrence-free survival? Analysis of a cohort of nephrectomies over 10 years.

Pablo A Rojas et al.PubMed ↗Publisher ↗

No numbers read from the abstract.